|Bid||177.60 x 1100|
|Ask||178.25 x 800|
|Day's range||176.17 - 179.13|
|52-week range||155.72 - 186.69|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||24.00|
|Earnings date||19 Jul 2022|
|Forward dividend & yield||4.52 (2.56%)|
|Ex-dividend date||23 May 2022|
|1y target est||190.67|
Meanwhile, things are even worse for the growth-dependent Nasdaq Composite (NASDAQINDEX: ^IXIC). Following its all-time high in November 2021, the Nasdaq has tumbled 27%. The Nasdaq's tumble officially places it in a bear market.
AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.
Markets are still volatile and that’s due in large part to the inflation we’ve felt for some time. This environment creates uncertainty.